Natco Pharma’s September quarter has two very different comparisons. Consolidated total revenue rose to ₹1,019.4 crore from ₹794.4 crore in the preceding quarter, but remained below ₹1,463.0 crore a year earlier. Profit after the share of associate income was ₹202.6 crore, against ₹206.5 crore sequentially and ₹517.9 crore a year earlier.

The company’s 13 November release attributes the annual revenue decline largely to lower Lenalidomide revenue, partly offset by growth in the base business. The right question is therefore how the revenue mix and the earnings bridge changed—not whether one percentage can describe the entire quarter.

Source: NATCO Q2 FY27 release, 13 November 2026, pages 1–2.

Consolidated measure, ₹ croreQ2 FY26Q1 FY27Q2 FY27
Total revenue1,463.0794.41,019.4
EBITDA, company definition679.2245.7310.0
PAT before associate share517.9122.2173.4
Share of associate profit—84.329.2
Profit after associate share517.9206.5202.6

Source: NATCO Q2 FY27 earnings presentation, consolidated profit and loss, PDF page 7.

The sequential profit bridge: operating recovery meets lower associate contribution

₹ crore

LabelValue (₹ crore)
Q1 PAT before associate122.2
Q2 PAT before associate173.4
Q1 associate share84.3
Q2 associate share29.2
Consolidated presentation, PDF page 7. These are accounting profit components, not cash receipts. Source: NATCO Q2 FY27 earnings presentation, consolidated profit and loss, PDF page 7

A ₹51.2 crore improvement met a ₹55.1 crore offset

Subtract the preceding quarter’s PAT before associate share from the current figure: ₹173.4 crore minus ₹122.2 crore equals a ₹51.2 crore improvement. The associate contribution fell by ₹55.1 crore, from ₹84.3 crore to ₹29.2 crore. Combine those changes and total profit fell ₹3.9 crore. That reconciles the apparently puzzling result: a substantial sales rebound alongside a small sequential profit decline.

The same calculation illustrates why the label PAT needs a definition. Comparing profit before associate share in one quarter with profit after associate share in another creates an artificial change. Use the same line on both sides, then identify which items explain the difference. A reconciliation is stronger evidence than an impression created by a large growth percentage.

Revenue growth was sequential; the annual base was much higher

Using the rounded total-revenue numbers, the sequential increase was about 28.3%, while the annual decline was about 30.3%. Neither cancels the other. One measures recovery against the immediately preceding quarter; the other shows the distance from last year’s earnings environment. The direction that matters for a valuation depends on what earnings level can be sustained, not which comparison looks more dramatic.

The release shows International Formulations revenue of ₹668.4 crore, up from ₹477.1 crore sequentially but down from ₹1,140.2 crore a year earlier. It includes profit share and subsidiaries in that line. Domestic formulations reached ₹145.7 crore, compared with ₹105.4 crore a year earlier. Those disclosures help explain why one large international line can outweigh growth elsewhere.

Source: NATCO Q2 FY27 release, 13 November 2026, pages 1–2.

Better sales did not restore the old margin

The company’s presentation reports EBITDA margins of 30.4% for the current quarter, 30.9% sequentially and 46.4% a year earlier. Its definition includes other income. The annual change is 16 percentage points, while the sequential change is 0.5 percentage points. These are changes in margin, not percentage declines in EBITDA.

To see the difference, imagine revenue of ₹100 and EBITDA of ₹30. A margin increase to 35% adds ₹5 if revenue stays unchanged. That is a five-percentage-point margin improvement and a 16.7% increase in EBITDA. If revenue instead falls, a better margin can still produce less EBITDA. Always keep the margin denominator beside the absolute profit number.

Source: NATCO Q2 FY27 earnings presentation, consolidated profit and loss, PDF page 7.

Associate accounting needs its own column

An associate’s share of profit is an accounting contribution to the investor’s earnings. It should not automatically be treated as cash received in the same period. Cash distributions, the carrying value of the investment and purchase-accounting adjustments need separate review. A larger ownership stake also does not guarantee a proportional increase in the current quarter’s recognised contribution when timing and accounting adjustments differ.

For a fictional business, ₹20 crore of recognised associate profit and ₹5 crore of cash dividends would represent two different measurements. Adding both to operating profit would double-count part of the economics. Replacing one with the other would answer a different question. The point is not that associate earnings are inferior; it is that earnings quality and available cash require more than one line.

A normalised earnings estimate needs evidence

When a pharmaceutical company benefits from a high-contribution product period, last year’s profit can be a difficult baseline. Extrapolating that peak assumes the commercial conditions continue. Extrapolating the weakest quarter assumes recovery never occurs. A useful middle path starts with products, competition, geography and the contribution of repeatable operations, then keeps unquantified pipeline opportunities outside the base calculation.

The same discipline applies to research spending and acquisitions. A cash outlay today may support future products, but it is not equivalent to a guaranteed future revenue stream. Check when a product can be sold, the competitive setting and the disclosed economics. Avoid converting a scientific or regulatory milestone into a sales forecast without those steps.

Three comparisons for the next result

First, compare total revenue and the major revenue lines on the same basis as this quarter. Second, reconcile EBITDA, tax and associate contributions to the final profit number. Third, compare operating cash generation and working capital with the accounting result. A recovery in reported profit with a build-up in receivables deserves different questions from a recovery supported by collections.

For portfolio analysis, distinguish a single-company earnings reset from a sector-wide conclusion. One fund may have a small Natco holding, another may have none, and a third may combine it with other pharmaceutical companies facing different product cycles. A dated security weight helps estimate exposure; a category label cannot establish that every pharma holding has the same earnings risk.

Questions readers ask

Why did Natco’s profit fall sequentially despite higher revenue?

PAT before associate share improved by ₹51.2 crore, but the associate contribution fell by ₹55.1 crore. Combined profit therefore declined by ₹3.9 crore using the presentation figures.

What was Natco’s Q2 FY27 consolidated total revenue?

The company reported ₹1,019.4 crore. It was higher than the preceding quarter’s ₹794.4 crore and below the year-earlier ₹1,463.0 crore.

Does share of associate profit equal cash received?

Not necessarily. Recognised associate profit and cash distributions are different accounting and cash-flow measures.

Check whether this company is already inside your funds

Use Stock Analysis to inspect available disclosed mutual-fund holdings, then open the relevant scheme in Fund Research. A monthly portfolio is a dated snapshot. For your own holdings, Portfolio Analysis can help identify exposure repeated through different funds. The headline and the size of your investment answer different questions.

About this analysis: Checked on 16 November 2026 using the dated sources below. Calculated figures use the stated inputs and rounding. Illustrative examples are not company forecasts. Cover: generated editorial illustration, not a photograph documenting the event. This article provides educational analysis without a buy or sell recommendation.